Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Beam Therapeutics (BEAM) EBITDA (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed EBITDA for 7 consecutive years, with $244.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 367.54% to $244.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$79.6 million, a 78.88% increase, with the full-year FY2025 number at -$79.6 million, up 78.88% from a year prior.
  • EBITDA was $244.6 million for Q4 2025 at Beam Therapeutics, up from -$111.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $244.6 million in Q4 2025 to a low of -$201.6 million in Q1 2021.
  • A 5-year average of -$62.4 million and a median of -$91.3 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 554.08% in 2021, then soared 502.78% in 2023.
  • Beam Therapeutics' EBITDA stood at -$64.8 million in 2021, then surged by 44.26% to -$36.1 million in 2022, then skyrocketed by 502.78% to $145.4 million in 2023, then crashed by 162.87% to -$91.4 million in 2024, then soared by 367.54% to $244.6 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's EBITDA are $244.6 million (Q4 2025), -$111.9 million (Q3 2025), and -$102.4 million (Q2 2025).